Daré Bioscience (DARE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting commenced at 9:00 A.M. Pacific Time with introductions of directors, executive officers, and the independent auditor representative.
Chairperson outlined meeting procedures, including voting and Q&A protocols.
Shareholder proposals
Eight proposals were presented, including director elections, auditor ratification, executive compensation, voting frequency, equity issuance, stock plan amendment, and potential adjournments.
Overview of voting outcomes
Gregory Matz and Sabrina Martucci Johnson elected as Class III directors.
Haskell & White LLP ratified as independent auditor for fiscal year 2026.
Executive compensation approved on an advisory basis; annual frequency preferred for future votes.
Approval granted for potential future share issuance to Lincoln Park and amendment to increase shares in the 2022 Stock Incentive Plan by 1,500,000.
Adjournment proposals for additional proxy solicitation, if needed, were approved.
Latest events from Daré Bioscience
- Women's health biotech pursues dual-path market strategy amid financial and listing risks.DARE
Registration filing - New product launches and key clinical milestones drive a pivotal growth phase.DARE
Investor update - Two women's health products launch in 2026, backed by a robust pipeline and strong funding.DARE
Corporate presentation - Revenue rose and losses narrowed, but going concern and Nasdaq delisting risks remain.DARE
Q2 2026 - Commercial launches and clinical milestones mark a pivotal growth phase, backed by strong funding.DARE
Virtual Investor Closing Bell - Imminent launches and clinical milestones position the pipeline for strong near-term growth.DARE
TD Cowen 46th Annual Health Care Conference - Okapi Partners LLC engaged for proxy solicitation ahead of the 2026 annual meeting.DARE
Proxy filing - Annual meeting on June 11, 2026, with virtual voting and emphasis on shareholder participation.DARE
Proxy filing - First product revenue expected June 2026, but ongoing viability depends on new capital.DARE
Q1 2026